ArticleJournal of cachexia, sarcopenia and muscle2017
Musculoskeletal decline and mortality: prospective data from the Geelong Osteoporosis Study.
Article in Journal of cachexia, sarcopenia and muscle, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- The evidence and impact of deprescribing on sarcopenia parameters: a systematic review.BMC geriatrics · 2025Pooled it
- The neglected association between schizophrenia and bone fragility: a systematic review and meta-analyses.Translational psychiatry · 2024Pooled it
- Global epidemiological features and impact of osteosarcopenia: A comprehensive meta-analysis and systematic review.Journal of cachexia, sarcopenia and muscle · 2024Pooled it
- Association of muscle wasting with mortality risk among adults: A systematic review and meta-analysis of prospective studies.Journal of cachexia, sarcopenia and muscle · 2023Pooled it
- Sarcopenia is associated with a greater risk of polypharmacy and number of medications: a systematic review and meta-analysis.Journal of cachexia, sarcopenia and muscle · 2023Pooled it
- Exploring the Association of Polypharmacy and Depressive Symptoms with Sarcopenia in Older Adults.Journal of clinical medicine · 2026Article
- The crossroads between osteosarcopenia and intrinsic capacity-a narrative review.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026Review
- Impact of nutritional status on mortality in geriatric patients with osteoporosis: a retrospective cohort study.BMC geriatrics · 2025Article
- Association between sarcopenia and osteoporosis: the cross-sectional study from NHANES 1999-2020 and a bi-directions Mendelian randomization study.Frontiers in endocrinology · 2024Article
- Association of dietary inflammatory indices with sarcopenia and all-cause mortality in COPD patients.Frontiers in nutrition · 2024Article
- Role of MOTS-c in the regulation of bone metabolism.Frontiers in physiology · 2023Review
- Musculoskeletal Deficits and Cognitive Impairment: Epidemiological Evidence and Biological Mechanisms.Current osteoporosis reports · 2022Review
- Is sarcopenia associated with anxiety symptoms and disorders? A systematic review and meta-analysis protocol.BMJ open · 2021Article
- The role of diet quality and dietary patterns in predicting muscle mass and function in men over a 15-year period.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2021Article
- Osteosarcopenia, an Asymmetrical Overlap of Two Connected Syndromes: Data from the OsteoSys Study.Nutrients · 2021Observational
- Lean mass as a risk factor for intensive care unit admission: an observational study.Critical care (London, England) · 2021Observational
- Osteoporotic patients treated with bisphosphonates do not show the increased mortality observed in those untreated.Journal of bone and mineral metabolism · 2021Article
- Non-alcoholic fatty liver disease and sarcopenia additively increase mortality: a Korean nationwide survey.Journal of cachexia, sarcopenia and muscle · 2021Article
- Identifying and Managing Malnutrition, Frailty and Sarcopenia in the Community: A Narrative Review.Nutrients · 2021Review
- T-Score and Handgrip Strength Association for the Diagnosis of Osteosarcopenia: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe aimed to examine the relationship between musculoskeletal deterioration and all-cause mortality in a cohort of women studied prospectively over a decade.
methodsA cohort of 750 women aged 50-94 years was followed for a decade after femoral neck bone mineral density (BMD) and appendicular lean mass (ALM) were measured using dual energy X-ray absorptiometry, in conjunction with comorbidities, health behaviour data, and other clinical measures. The outcome was all-cause mortality identified from the Australian National Deaths Index. Using Cox proportional hazards models and age as the time variable, mortality risks were estimated according to BMD groups (ideal-BMD, osteopenia, and osteoporosis) and ALM groups (T-scores > -1.0 high, -2.0 to -1.0 medium, <-2.0 low).
resultsDuring 6712 person years of follow-up, there were 190 deaths, the proportions increasing with diminishing BMD: 10.7% (23/215) ideal-BMD, 23.5% (89/378) osteopenia, 49.7% (78/157) osteoporosis; and with diminishing ALM: 17.0% (59/345) high, 26.2% (79/301) medium, 50.0% (52/104) low. In multivariable models adjusted for smoking, polypharmacy, and mobility, compared with those with ideal BMD, mortality risk was greater for those with osteopenia [hazard ratio (HR) 1.77, 95% confidence interval (CI) 1.11-2.81] and osteoporosis (HR 2.61, 95%CI 1.60-4.24). Similarly, compared with those with high ALM, adjusted mortality risk was greater for medium ALM (HR 1.36, 95%CI 0.97-1.91) and low ALM (HR 1.65, 95%CI 1.11-2.45). When BMD and ALM groups were tested together in the model, BMD remained a predictor of mortality (HR 1.74, 95%CI 1.09-2.78; HR 2.82, 95%CI 1.70-4.70; respectively), and low ALM had borderline significance (HR 1.52, 95%CI 1.00-2.31), which was further attenuated after adjusting for smoking, polypharmacy, and mobility.
conclusionsPoor musculoskeletal health increased the risk for mortality independent of age. This appears to be driven mainly by a decline in bone mass. Low lean mass independently exacerbated mortality risk, and this appeared to operate through poor health exposures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.